- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 626KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 153KB)
Nivolumab – March 2024
Nivolumab (NSCLC): Injection concentrate for I.V. infusion 100 mg in 10 mL, Injection concentrate for I.V. infusion 40 mg in 4 mL; Opdivo®
Last updated
30 May 2025